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Edited by Varda RotterAbstract Remarkably, a cancer cell rarely possesses two mu-
tant p53 proteins. Instead, mutation of one allele is usually asso-
ciated with loss of the second p53 allele. Why do not two mutant
p53 co-exist? We hypothesize that two diﬀerent p53 may comple-
ment each other, when expressed at equal levels. By titrating
trans-deﬁcient and DNA-binding-deﬁcient p53 in cells with mu-
tant p53 and by co-transfecting distinct mutant p53 in p53-null
cells, we demonstrated activation of p53-dependent transcription.
We suggest that, due to complementation of two mutant p53,
cancer cells need to delete the second p53 allele rather than mu-
tate it.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Inactivation of the p53 tumor suppressor is the most com-
mon alteration in human cancer [1,2]. Usually, mutant p53 is
associated with the loss of the second p53 allele, known as loss
of heterozygosity (LOH) [3]. Wild-type (wt) p53, a transcrip-
tion factor, transactivates numerous genes that cause growth
arrest and apoptosis [1–7]. Also, wt p53 induces Mdm-2, which
in turn targets p53 for degradation [8,9] (Fig. 1A). Since mu-
tant p53 cannot induce Mdm-2, mutant p53 is not degraded
(stable) and accumulates (Fig. 1B). Mutant p53 is stable only
in the absence of wt p53 allele (Fig. 1). In the presence of wt
p53, mutant p53 is unstable, because wt p53 induces Mdm-2,
which in turn degrades both wt and mutant p53s [10–13],
which then are equally increased (Fig. 1C). Although, when
overexpressed by transfection, an ectopic mutant p53 inhibits
wt p53 (dominant-negative eﬀect), an endogenous mutant
p53 cannot inhibit wt p53 [11]. In fact, mutant and wt p53
form tetramers, which retain half of p53 activity [14]. Further-
more, when in excess, wt p53 is dominant over mutant p53
[12,15–18]. Therefore, the second p53 allele must be either mu-
tated or deleted. DNA damaging carcinogens frequently cause
point mutations [19]. Furthermore, mutant p53 can exert dom-*Corresponding author. Address: Cancer Center, Ordway Research
Institute, 150 New Scotland Avenue, Albany, NY 12208, United
States.
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activators and by trans-activating additional genes [20–25].
Thus, it is expectable that a cancer cell may end-up with two
mutant p53. However, inactivation of both p53 alleles by
mutations is extremely rare. There is only one well-known can-
cer cell line with two mutant p53s: DU145 (prostate cancer cell
line), which expresses p53-223Leu and p53-274Phe [26,27]. In
other cases, one p53 is mutant and the other p53 is deleted
(LOH). Why do not two p53 mutants co-exist? In order to
trans-activate, wt p53 proteins form a tetramer that binds
DNA [28,29]. Also, mutant p53 form active tetramers with
wt p53 [14] and enhance the transcriptional activity of wt
p53 [30]. When translated together with p53 lacking trans-
domain (del 1–25), DNA-binding-deﬁcient p53 can bind
DNA [14]. We hypothesize that, when co-expressed, such
mutant p53s regain a wt trans-activation function.
On the other hand, two mutant p53 that do not compensate
each other (or, in contrast, cooperate to gain oncogenic func-
tions) can co-exist in a cancer cell. For example, 223Leu and
274Phe cooperate to gain oncogenic functions, thus explaining
why DU145 cells possess two mutant p53s [27]. This exception
just conﬁrms the rule.
Finally, conformation of mutant p53 (and wt p53) is ﬂexible
and can be inﬂuenced by interaction with other molecules,
including Hsp90 [26,31], small molecules [32–34], peptides
[35,36] and co-expressed p53s [37]. 273H, a DNA contact mu-
tant p53, has wt conformation and may in theory change con-
formation of 173H (mutant-conformation p53). Despite these
circumstantial reasons, direct evidence that two mutant p53
can actually trans-activate was missing. Here we address this
question.2. Materials and methods
2.1. Cell lines
Human prostate cancer cell lines, DU145 and PC3M; human breast
cancer cell lines, SKBr3 and MCF-7 were obtained from American
Type Culture Collection (Manassas, VA) and used previously
[12,26,38].2.2. Immunoblot
Proteins were harvested in TNESVF buﬀer and equal quantities of
proteins were resolved by gel electrophoresis on either 7.5% SDS–
PAGE or NuPAGE 4–12% Bis-Tris gel with MOPS running buﬀer
(NOVEX, San Diego, CA) according to manufactures instructions.
Immunoblotting was performed using mouse monoclonal antihuman
p21 (Oncogene Res., Calbiochem), antihuman p53 (Ab-6 and Ab-2,
Calbiochem, Cambridge, MA). Secondary antibody was anti-mouseblished by Elsevier B.V. All rights reserved.
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Fig. 2. Trans-activation domain deﬁcient mutant p53-N25-del and
p53-22/23 induce PG13-Luc in DU145 cells. (A) DU145 cells were co-
transfected with 1 lg PG13-Luc and indicated amount (ng) of either
p53-N25-del or p53-22/23-expressing plasmids. (B) DU145 cells were
co-transfected with CMV-Luc and p53-22/23 mutant p53-expressing
plasmid. Total amount of DNA was normalized by 2 lg with empty
vector. After 16 h, cells were lysed and luciferase activity was
measured.
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Fig. 1. Loss of the second p53 allele is necessary to lose p53 function
and to stabilize mutant p53. (A) Wt p53 (two wt alleles) transcrip-
tionally induces Mdm-2, which targets p53 for degradation. Levels of
wt p53 are low (small p53). (B) One p53 allele is mutant, the second
allele is lost (LOH). Mutant p53 is not degraded because it cannot
transactivate Mdm-2. Therefore, mutant p53 is accumulated at high
levels (big p53). (C) One p53 allele is mutant, the second allele is wt. Wt
p53 induces Mdm-2, which degrades both wt p53 and mutant p53.
Both mutant p53 and wt p53 are expressed at similar (low) levels.
2232 Z.N. Demidenko et al. / FEBS Letters 579 (2005) 2231–2235or anti-rabbit Ig horseradish peroxidase-linked (Amersham, Piscata-
way, NJ). The membrane was developed using ECLeWestern blotting
detection reagents (Amersham).
2.3. Transient transfection
WWP-Luc, a p21 promoter-luciferase construct, and PG13-Luc,
containing 13 generic p53 response elements were obtained from Dr.
El-Deiry [39]. The control luciferase plasmid, pGL2-Control, driven
by SV40 promoter and enhancer sequences, was purchased from Pro-
mega (Madison, WI). pCMV–galactosidase was purchased from Clon-
tech (Palo Alto, CA). Wt p53, 175His, 273His mutant p53 were
obtained from Dr. Vogelstein. The p53 expression plasmid consists
of wt or mutant p53 cDNA cloned into the BamHI site of pREP4
(Invitrogen).
50 · 103 and 200 · 103 cells/well were plated in 24- and 6-well plates,
respectively (Costar, Acton, MA). The next day, cells were transfected
with plasmids in the presence of Lipofectamine (Gibco-BRL, Gaithers-
burg, MD) or with TransFast Transfection Reagent (Promega) accord-
ing to manufacture recommendations. 6 h later, the medium was
changed for additional 24 h, unless otherwise indicated. Luciferase
activity was measured as described previously [12].3. Results
3.1. Trans-deﬁcient p53 induces transcription in DU145 and
SKBr3 cells
To address the question whether two mutant p53 can com-
plement each other (compensate for the loss of functions),
we transfected DU145 cells using transactivation-deﬁcient mu-
tant p53s: namely, p53 with a double-point mutation 22/23
(p53-22/23) and p53 lacking 25 amino acids on the N-end
(p53-N25-del). The NH2-end of p53 is a transactivation do-
main [40]. These mutant p53 cannot bind a transcription co-
activator p300/CBP. Both mutant p53 still bind DNA.
DU145 cells contain two endogenous mutant p53, which in
contrast cannot bind to DNA. DU145 cells were chosen to
maximize the chances that at least one endogenous mutant
p53 will interact with p53-22/23 and p53-N25-del. We expected
that the p53 transcription factor may bind DNA and transac-
tivate via transfected and endogenous p53.
We found that transfection with 8–40 ng plasmid DNA/well
of either p53-N25-del or p53-22/23 induced PG13-Luc in
DU145 cells (Fig. 2). As a negative control, these mutants
did not transactivate CMV-Luc (Fig. 2B). By increasing an
amount of transfected p53, we observed a decrease in transac-
tivation of PG13-Luc. At 1000 ng/well, both p53-22/23 and
p53-N25-del suppressed PG13-Luc, returning its expressionto the basal level (Fig. 2A). Similar results were obtained in
SKBr3 breast cancer cell line having 175H mutant, which is
deﬁcient in DNA binding (data not shown).
3.2. Co-transfection of N-deﬁcient and 273H mutants
transactivates PG13-Luc in PC3M
Next, we co-transfected two mutant p53 plus PG13-Luc in
PC3M cells, which have no endogenous p53 (p53 null). In con-
trol, PG13-Luc was expressed at very low levels, reﬂecting lack
of endogenous p53 in PC3M cells (Fig. 3). As a positive con-
trol, transfection with wt p53 dramatically induced PG13-
Luc. 273H, a contact mutant, is one of the most common in
human cancer. As expected, this mutant p53 did not transacti-
vate PG13-Luc (Fig. 3). In PC3M, p53-N25-del and p53-22/23
display lower activities than wt p53. It was diﬃcult to co-trans-
fect mutant p53s at equivalent levels. Yet, when p53-N25del
and 273H were expressed at similar levels, then 273H potenti-
ated p53-N25-del (Fig. 3: N25 +273). At the same conditions,
273H also potentiated p53-22/23 (Fig. 3: 22/23 +273).
3.3. Dose-dependent reversal of co-activation in PC3M
Next, we wished to conﬁrm that an excess of p53-N25-del
can reverse co-activation of PG13-Luc (Fig. 4). We started
with the condition of equal expression, as found in Fig. 3.
When co-expressed at equal levels, p53-N25-del and 273H
stimulated PG13-Luc (Fig. 4A and B). Then, while keeping
constant expression of 273H, we increased expression of
Fig. 3. Mutant 273H (273) potentiates the trans-activity of p53-22/23
and p53-N25-del. PC3M cells were transfected with 1 lg/well PG13-
Luc and co-transfected with plasmids expressing indicated p53s: p53-
22/23, p53-N25-del, H273 either alone (1 lg/well) or in combinations
(0.5 lg/well plus 05 lg/well). Total amount of DNA is 2 lg/well. Upper
panel: luciferase activity (PG13-Luc) was measured at day 1 and 2.
Lower panel: p53 protein was measured by immunoblot at day 1. Wt
p53, p53-22/23 and 273H are seen as full length p53. p53-N25-del, with
lower molecular mass, is seen below.
Fig. 4. Co-expression of mutant 273H (273) and p53-N25-del. PC3M
cells were transfected with 1 lg/well PG13-Luc and co-transfected with
40 ng/well 273H and increasing amounts of N-del 25 (0–1000 ng/well).
(A) Luciferase activity (PG13-Luc) was measured at day 1. (B) p53
protein was measured by immunoblot at day 1.
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served the abrogation of activation of PG13-Luc. It is note-
worthy that, when transcription was activated (at 20 ng
p53-N25-del plasmid DNA/well), levels of 273H were de-
creased, compared with either no p53-N25-del or high levelsFig. 5. Comparison of transactivation, complementation and dominant-nega
1 lg/well PG13-Luc and either wt p53 (left column) or 273H (right column)
SKBr3 (C) and MCF-7 (D) cells were co-transfected with 1 lg/well PG13-Lu
well. Luciferase activity was measured after 24 h. The luciferase activity is shof p53-N25-del (Fig. 4B). This is consistent with degradation
of mutant 273H, in the presence of the p53 function.
3.4. Co-activation by two DNA binding mutants
Finally, we wished to conﬁrm that two natural mutant p53s,
when co-expressed together, can transactivate PG13-Luc. We
compared eﬀects of wt p53 and 273H in cells lacking p53
(PC3M), cells expressing 175H p53 (SKBr3) and cells express-
ing wt p53 (MCF-7). Both wt p53 and 273H were expressed in
PC3M in a dose-dependent manner (Fig. 5, upper panel). Wt
p53 induced PG13-Luc transcription, whereas 273H did not
(Fig. 5, PC3M). Also, wt p53 induced PG13-Luc transcription
in SKBr3 cells. Noteworthy, at 20 ng/well, wt p53 induced ative eﬀects caused by 273H. (A, B) PC3M cells were co-transfected with
: 0–2000 ng/well. (A) p53 and (B) luciferase were measured after 24 h.
c and either wt p53 (left column) or 273H (right column): 0–2000 ng/
own as percent of control (p53 = 0) ± m.
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half-maximal transcription in SKBr3 (endogenous 175H) cells,
due to competition between wt p53 and endogenous mutant
p53 (dominant-negative eﬀect). This actually indicates that
transfection with 20 ng p53-expressing plasmid/well yields
physiological levels of p53 expression. In agreement, 20 ng
273H induced PG13-Luc in SKBr3 cells, which have endoge-
nous 175H. At higher levels, 273H did not induce PG13-Luc.
In agreement, high levels of 273H exerted dominant-negative
eﬀect against wt p53 (Fig. 5, MCF-7).4. Discussion
The tumor suppressor p53 is mutated in 50% of cancers.
When one p53 is mutated, the second allele is usually deleted
(LOH). Why the second allele is not mutated as well. To
explain why two diﬀerent mutant p53 do not usually co-exist
in a cancer cell, we suggest that, when co-expressed in the same
cell, two mutant p53 can regain trans-activation functions.
This suggestion is not entirely surprising. Numerous transcrip-
tion factors (AP-1, HIF-1, etc.) are heteromers with subunits
that are not necessarily active as homomers. In this light,
two diﬀerent mutant p53s are distinct subunits that are
inactive as homotetramers but can form heterotetramers.
Here, we showed that the co-expression of DNA-binding-
deﬁcient mutants (273H or 175H) with p53 mutants that can
bind DNA (p53-22/23 or p53-N25-del) results in trans-activity.
We conclude that the p53 transcription factor binds DNA via
p53-22/23 (or p53-N25-del) and trans-activate via 273H (or
175H). Furthermore, when co-expressed at equal levels, 273H
and 175H caused transactivation of PG13-Luc. If one of the
mutants is in access, it exerts dominant-negative eﬀect. In
agreement, high levels of 273H inhibited PG13-Luc in SKBr3
(175H) and in MCF-7 (wt p53) cells. The stoichiometry of the
mixed complexes, under transactivating and non-transactivat-
ing conditions, can be planned for further investigations.
Obviously, two mutant p53 with identical mutations will not
complement each other. The chances that two alleles are mu-
tated at the same nucleotide, however, are low. Perhaps such
identical mutations rarely occur but are perceived as one muta-
tion, not two independent mutations. Also, similar mutants
are unlikely complementary. For example, in DU145 cells,
two endogenous p53 mutants do not acquire wt functions
but instead gain new functions [27]. Interestingly, in DU145
cells, mutant p53 are especially prone to destabilization by gel-
danamycin, which partially rescue wt functions [26], implying
that two mutant p53 can acquire trans-functions.
If two mutant p53 do not co-exist to avoid wt function, then
why 50% cancer cells have wt p53, thus retaining wt function.
The simplest answer is that some cancer cells prefer wt func-
tion to start with. Such cancer cell lines are apoptosis-reluctant
(due to inactivation of caspases in MCF-7 cells, for instance,
and Apaf-1 in melanoma cells [41], for instance). Whereas can-
cer cells with mutant p53 cannot tolerate exogenous wt p53,
cells with wt p53 are relatively resistant to apoptosis [18]. Cells
with wt p53 may actually beneﬁt from retaining wt p53 [42].
Yet, if a cell needs to inactivate p53, it acquires either null or
LOH phenotype. In other words, if there is a selective pressure
against the wt p53 function, a cell cannot end up with two
mutant p53 that compensate each other.References
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